Developing molecules that individually harness the combined effect of
immune-mediated
and
direct anti-tumour activity

FIND OUT MORE GET IN TOUCH

Our Pipeline

iOnctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program.

our current projects

Pipeline

–

WHO WE ARE

Catherine Pickering

Catherine Pickering, CEO

Catherine holds a PhD in Medicinal Chemistry from The Institute of Cancer Research, London and an MBA from Henley Management College, UK. She is an experienced deal maker with broad transaction experience including licensing (in- and out licensing, option deals, and strategic collaborations) and M&A.
Lars van der Veen

Lars van der Veen, COO

Lars holds a PhD in homogeneous catalysis (cum laude) from the University of Amsterdam. He is an experienced project and alliance manager with demonstrated leadership in pre-clinical and clinical development. He has managed >25 alliances for in-licensed and out-licensed products of both biologics and small molecules, driving governance, delivery of results and issue resolution.
Zoe Johnson

Zoë Johnson,
CSO

Zoë holds a PhD in Pharmacology from King's College London, UK. Zoë has more than 15 years of experience in the biopharmaceutical industry in the UK and Europe where she has worked across a range of therapy areas including oncology, autoimmune & inflammatory diseases and allergy.
Michael Lahn

Michael Lahn, CMO

Michael holds a MD in Medical Microbiology from the University of Mainz. He has over 20 years’ experience in oncology clinical development in the pharmaceutical industry, where he was responsible for the development of multiple molecules through early and late clinical development.
MEET THE TEAM

HOW WE'RE FIGHTING CANCER

iOnctura is developing a pipeline of best in class molecules that harness the combined effect of immune-mediated and direct anti-tumour activity with an aim to deliver molecules with superior clinical efficacy and safety in oncology

MORE
Cancer Research UK Merck Dutch Cancer Institute
LATEST NEWS
View all news >

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH